AI Engines For more Details: Perplexity Kagi Labs You
Gram-Negative Infections: Azlocillin is particularly effective against gram-negative bacteria. It may be used to treat infections caused by bacteria such as Pseudomonas aeruginosa, Escherichia coli, Klebsiella species, and Proteus species.
Lower Respiratory Tract Infections: Azlocillin may be prescribed to treat lower respiratory tract infections such as pneumonia, particularly those caused by gram-negative bacteria.
Urinary Tract Infections (UTIs): Azlocillin can be used to treat urinary tract infections caused by susceptible bacteria.
Intra-Abdominal Infections: It may be used to treat intra-abdominal infections, including peritonitis, caused by susceptible bacteria.
Skin and Soft Tissue Infections: Azlocillin may be effective in treating skin and soft tissue infections caused by susceptible bacteria.
Gynecological Infections: In some cases, azlocillin may be used to treat gynecological infections caused by susceptible bacteria.
Sepsis: Azlocillin may be used as part of the treatment regimen for sepsis caused by susceptible bacteria.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.6 | 0.9 | -0.5 |
| ADHD | 5.4 | 0.9 | 5 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.4 | 3.5 | -0.03 |
| Allergies | 8.1 | 4.6 | 0.76 |
| Allergy to milk products | 2.6 | 1.6 | 0.63 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 7.7 | 7.7 | 0 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 4.3 | 1.5 | 1.87 |
| Ankylosing spondylitis | 5.3 | 1.8 | 1.94 |
| Anorexia Nervosa | 2.1 | 3.2 | -0.52 |
| Antiphospholipid syndrome (APS) | 2 | 2 | |
| Asthma | 6.5 | 3.4 | 0.91 |
| Atherosclerosis | 2.6 | 3 | -0.15 |
| Atrial fibrillation | 4.1 | 2.8 | 0.46 |
| Autism | 12.3 | 11.6 | 0.06 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 3 | 3 | |
| Bipolar Disorder | 2.1 | 1.7 | 0.24 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 1.2 | 1.2 | |
| Cancer (General) | 0.9 | 3.4 | -2.78 |
| Carcinoma | 4.7 | 2.6 | 0.81 |
| Celiac Disease | 3.5 | 4 | -0.14 |
| Cerebral Palsy | 1.9 | 1.3 | 0.46 |
| Chronic Fatigue Syndrome | 6.5 | 7.1 | -0.09 |
| Chronic Kidney Disease | 5.2 | 3.1 | 0.68 |
| Chronic Lyme | 1.1 | 0.8 | 0.38 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.9 | 2 | 0.45 |
| Chronic Urticaria (Hives) | 2 | 1.8 | 0.11 |
| Coagulation / Micro clot triggering bacteria | 1.9 | 1.3 | 0.46 |
| Cognitive Function | 3.6 | 1.6 | 1.25 |
| Colorectal Cancer | 9.8 | 2.8 | 2.5 |
| Constipation | 2.1 | 0.7 | 2 |
| Coronary artery disease | 3 | 3 | 0 |
| COVID-19 | 11.5 | 14.3 | -0.24 |
| Crohn's Disease | 10.1 | 6.9 | 0.46 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.2 | 1.9 | -0.58 |
| d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
| deep vein thrombosis | 4.2 | 1.4 | 2 |
| Denture Wearers Oral Shifts | 2.1 | 2.1 | |
| Depression | 13.7 | 11.6 | 0.18 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2.3 | 2.6 | -0.13 |
| Endometriosis | 3.5 | 2.6 | 0.35 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 4.5 | 2.8 | 0.61 |
| erectile dysfunction | 2.6 | 0.3 | 7.67 |
| Fibromyalgia | 3.7 | 2.6 | 0.42 |
| Functional constipation / chronic idiopathic constipation | 6.9 | 4.9 | 0.41 |
| gallstone disease (gsd) | 4.3 | 1.6 | 1.69 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.4 | 1.2 | 1 |
| Generalized anxiety disorder | 3.9 | 3 | 0.3 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.6 | 1.3 | 1 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 2 | -1.22 |
| Halitosis | 1.8 | 0.3 | 5 |
| Hashimoto's thyroiditis | 4.4 | 2 | 1.2 |
| Heart Failure | 5.4 | 2.4 | 1.25 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 1.9 | 0.6 | 2.17 |
| hypercholesterolemia (High Cholesterol) | 1.1 | 0.6 | 0.83 |
| hyperglycemia | 3 | 2.2 | 0.36 |
| Hyperlipidemia (High Blood Fats) | 1.1 | 0.3 | 2.67 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 6.3 | 5.9 | 0.07 |
| Hypothyroidism | 1 | 1 | 0 |
| Hypoxia | 4.1 | 0.9 | 3.56 |
| IgA nephropathy (IgAN) | 1.9 | 4.9 | -1.58 |
| Inflammatory Bowel Disease | 11 | 11.5 | -0.05 |
| Insomnia | 2.5 | 3.5 | -0.4 |
| Intelligence | 2 | 1.1 | 0.82 |
| Intracranial aneurysms | 1.4 | 0.9 | 0.56 |
| Irritable Bowel Syndrome | 9.4 | 6.4 | 0.47 |
| ischemic stroke | 3.7 | 1.7 | 1.18 |
| Liver Cirrhosis | 8.9 | 5.7 | 0.56 |
| Long COVID | 8.1 | 8.4 | -0.04 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.2 | 1.6 | -0.33 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.5 | 0.9 | 0.67 |
| ME/CFS with IBS | 1 | 2.4 | -1.4 |
| ME/CFS without IBS | 2 | 2.4 | -0.2 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 1 | 1.1 |
| Metabolic Syndrome | 8.6 | 9.3 | -0.08 |
| Mood Disorders | 13.6 | 9.5 | 0.43 |
| multiple chemical sensitivity [MCS] | 1.7 | 0.1 | 16 |
| Multiple Sclerosis | 9.2 | 7 | 0.31 |
| Multiple system atrophy (MSA) | 2.3 | 0.7 | 2.29 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 3.6 | -11 |
| Neuropathy (all types) | 1.7 | 2.8 | -0.65 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.2 | 1.2 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 6.5 | 5.9 | 0.1 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 12.6 | 10.6 | 0.19 |
| obsessive-compulsive disorder | 7 | 4.8 | 0.46 |
| Osteoarthritis | 3.3 | 1.7 | 0.94 |
| Osteoporosis | 2.5 | 1.9 | 0.32 |
| pancreatic cancer | 1.2 | 0.3 | 3 |
| Parkinson's Disease | 10.3 | 8.3 | 0.24 |
| Polycystic ovary syndrome | 7.9 | 3.4 | 1.32 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.7 | -0.42 |
| Primary sclerosing cholangitis | 3 | 3.2 | -0.07 |
| Psoriasis | 4.4 | 4 | 0.1 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 9.3 | 4.7 | 0.98 |
| Rosacea | 1.2 | 1 | 0.2 |
| Schizophrenia | 7.6 | 3.6 | 1.11 |
| scoliosis | 0.9 | 0.9 | 0 |
| sensorineural hearing loss | 0.5 | 0.5 | |
| Sjögren syndrome | 3.2 | 3.2 | 0 |
| Sleep Apnea | 2.2 | 1.8 | 0.22 |
| Slow gastric motility / Gastroparesis | 1.5 | 0.3 | 4 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2.2 | 0.6 | 2.67 |
| Stress / posttraumatic stress disorder | 3.7 | 3.3 | 0.12 |
| Systemic Lupus Erythematosus | 4.6 | 2.4 | 0.92 |
| Tic Disorder | 1.5 | 1.8 | -0.2 |
| Tourette syndrome | 1.4 | 0.3 | 3.67 |
| Type 1 Diabetes | 4.8 | 4.4 | 0.09 |
| Type 2 Diabetes | 10.1 | 9 | 0.12 |
| Ulcerative colitis | 7 | 7.9 | -0.13 |
| Unhealthy Ageing | 6.4 | 2.9 | 1.21 |
| Vitiligo | 2.5 | 2 | 0.25 |
